Send to

Choose Destination
Cancer Immunol Immunother. 2003 Oct;52(10):638-42. Epub 2003 Jun 14.

Enhanced expression of the complement regulatory protein CD55 predicts a poor prognosis in colorectal cancer patients.

Author information

CRC Academic Department of Clinical Oncology, City Hospital, Hucknall Road, NG5 1PB, Nottingham, Nottinghamshire, UK.


This study prospectively correlated the level of expression of CD55 on tumours with 7-year survival in 136 colorectal cancer patients. Patients with tumours expressing high levels of CD55 had a significantly worse survival (24%) than patients with low CD55 levels (50%, p<0.02). A similar difference was seen for patients (Duke's B or C) with a high risk of recurrence (29% vs 58%, p<0.05). Furthermore, there was a progressive deterioration in prognosis with increasing antigen expression ( p=0.01). It remains unclear if CD55 is overexpressed by tumours to protect them from complement or if it is related to the recent observation that CD55 is a ligand for the T-cell activation antigen CD97. However, it is a marker of aggression, as colorectal cancer patients whose tumours overexpress CD55 have a significantly reduced 7-year survival.

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center